Reckitt Benckiser Company Profile
✉ Email this page to a colleague
What is the competitive landscape for RECKITT BENCKISER
RECKITT BENCKISER has five approved drugs.
There are three US patents protecting RECKITT BENCKISER drugs.
There are seven patent family members on RECKITT BENCKISER drugs in four countries and nine supplementary protection certificates in eight countries.
Summary for Reckitt Benckiser
| International Patents: | 7 |
| US Patents: | 3 |
| Tradenames: | 5 |
| Ingredients: | 5 |
| NDAs: | 5 |
| Patent Litigation for Reckitt Benckiser: | See patent lawsuits for Reckitt Benckiser |
Drugs and US Patents for Reckitt Benckiser
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reckitt Benckiser | MUCINEX 12HR COLD & FEVER MULTI-SYMPTOM | dextromethorphan hydrobromide; guaifenesin; naproxen sodium | TABLET, EXTENDED RELEASE;ORAL | 217338-001 | Dec 22, 2025 | OTC | Yes | Yes | 12,370,189 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Reckitt Benckiser | MUCINEX D | guaifenesin; pseudoephedrine hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 021585-001 | Jun 22, 2004 | OTC | Yes | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Reckitt Benckiser | MUCINEX D | guaifenesin; pseudoephedrine hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 021585-002 | Jun 22, 2004 | OTC | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Reckitt Benckiser
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Reckitt Benckiser | MUCINEX D | guaifenesin; pseudoephedrine hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 021585-001 | Jun 22, 2004 | 7,838,032 | ⤷ Start Trial |
| Reckitt Benckiser | MUCINEX D | guaifenesin; pseudoephedrine hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 021585-001 | Jun 22, 2004 | 6,372,252 | ⤷ Start Trial |
| Reckitt Benckiser | MUCINEX | guaifenesin | TABLET, EXTENDED RELEASE;ORAL | 021282-001 | Jul 12, 2002 | 6,372,252 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for RECKITT BENCKISER drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Extended-release Tablets | 600 mg and 1.2 gm | ➤ Subscribe | 2006-06-09 |
| ➤ Subscribe | Extended-release Suspension | 30 mg/5 mL | ➤ Subscribe | 2009-01-12 |
| ➤ Subscribe | Extended-release Tablets | 600 mg/30 mg and 1200 mg/60 mg | ➤ Subscribe | 2008-12-17 |
International Patents for Reckitt Benckiser Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2017062997 | ⤷ Start Trial |
| Canada | 2965256 | ⤷ Start Trial |
| European Patent Office | 3209286 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Reckitt Benckiser Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1539166 | 2013/055 | Ireland | ⤷ Start Trial | PRODUCT NAME: THE COMBINATION OF: (A) DEXTROMETHORPHAN OR A PHARMACEUTICALLY ACCEPTABLE SALT, PRECURSOR OR DERIVATIVE THEREOF, E.G. DEXTROMETHORPHAN HYDROBROMIDE AND IN PARTICULAR DEXTROMETHORPHAN HYDROBROMIDE MONOHYDRATE; AND (B) QUINIDINE OR A PHARMACEUTICALLY ACCEPTABLE SALT, PRECURSOR OR DERIVATIVE THEREOF, E.G. QUINIDINE SULPHATE AND IN PARTICULAR QUINIDINE SULPHATE DIHYDRATE, PROTECTED BY THE BASIC PATENT; REGISTRATION NO/DATE: EU/1/13/833 20130624 |
| 1539166 | 2013C/064 | Belgium | ⤷ Start Trial | PRODUCT NAME: DEXTROMETHORPHANE OU UN SEL, PRCURSEUR DE DERIVE PHARMACEUTIQUEMENT ACCEPTABLE, PAR EXEMPLE LE BROMHYDRURE DE DEXTROMETORPHANE ET EN PARTICULIER LE BROMHYDRURE DE DEXTROMETROPHANE MONHYDRATE ET QUINIDINE OU UN SEL,....; AUTHORISATION NUMBER AND DATE: EU/1/13/833 20130626 |
| 1539166 | 122013000090 | Germany | ⤷ Start Trial | PRODUCT NAME: KOMBINATION AUS: (A) DEXTROMETHORPHAN ODER EINEM PHARMAZEUTISCH VERTRAEGLICHEN SALZ, Z.B. DEXTROMETHORPHAN-HYDROBROMID UND INSBESONDERE DEXTROMETHORPHAN-HYDROBROMID-MONOHYDRAT; UND (B) CHINIDIN ODER EINEM PHARMAZEUTISCH VERTRAEGLICHEN SALZ DAVON, Z.B.CHINIDIN-SULFAT UND INSBESONDERE CHINIDIN-SULFAT-DIHYDRAT; REGISTRATION NO/DATE: EU/1/13/833 20130624 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
